- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01550549
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Avid has previously developed a florbetapir-PET scan binary read methodology and training program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369), 18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies, training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of this training program suitable for web-based distribution. Nuclear medicine physicians will complete the automated training program then read the florbetapir-PET images from 151 subjects with repeat readings of 33 randomly selected images. Readers will rate each case as either positive for significant tracer accumulation in cortical gray matter or negative for significant tracer accumulation in cortical gray matter. The inter-rater reliability, sensitivity and specificity of the readers will be evaluated.
The primary image set for determination of inter-reader agreement is comprised of images from 119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20 with mild cognitive impairment) MCI, 20 with AD.
Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients that were not used in the training program (n=32); 13 of these 32 scans presented for repeat reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased the number of unique cases in the validation dataset to 151 scans with 33 scans repeated yielding a total of 184 scans reviewed by the readers.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Eligibility for subjects scans to be used in this study is determined by subject's eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).
Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- Have probable AD per National Institute of Neurological and Communication Disorders and Stroke (NINCDS) criteria
- Mini mental state exam (MMSE) score between 10 and 24 inclusive
Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):
- Male or female at least 50 years of age
- Complaints of memory or cognitive decline corroborated by an informant
- Clinical dementia rating of 0.5
- No obvious cause for cognitive impairment (eg, head trauma or stroke)
- Cognitive impairment onset within the past year
- MMSE score greater than 24
Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- MMSE score greater than or equal to 29 and cognitively normal by informant report and psychometric test battery at screening
Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):
- Male or female 18 years or older
- Projected life expectancy of less than 6 months
- Consent to brain donation
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Enda
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Inter-rater Reliability
Tidsram: Scan acquired 50-60 min post-injection
|
Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa.
All scans were read in a blinded fashion without access to clinical information.
|
Scan acquired 50-60 min post-injection
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Tidsram: at autopsy, within 2 years of scan
|
Calculated as the percent of true positives which are correctly identified
|
at autopsy, within 2 years of scan
|
Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
Tidsram: at autopsy, within 2 years of scan
|
Calculated as the percent of true negatives which are correctly identified
|
at autopsy, within 2 years of scan
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Median Sensitivity and Specificity vs. CERAD Diagnosis
Tidsram: Baseline scan
|
Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).
|
Baseline scan
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 18F-AV-45-PT01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Neurodegenerativa sjukdomar
-
University of PennsylvaniaAvid RadiopharmaceuticalsRekrytering
-
ACADIA Pharmaceuticals Inc.AvslutadNeuropsykiatriska symtom relaterade till neurodegenerativ sjukdomFörenta staterna, Ryska Federationen, Serbien, Polen, Georgien, Tjeckien, Bulgarien, Colombia, Mexiko, Rumänien, Sydafrika, Ukraina
-
National Institute of Neurological Disorders and...Avslutad
-
ACADIA Pharmaceuticals Inc.AvslutadNeuropsykiatriska symtom relaterade till neurodegenerativ sjukdomSerbien, Förenta staterna, Polen, Georgien, Ryska Federationen, Bulgarien, Colombia, Tjeckien, Mexiko, Rumänien, Sydafrika, Ukraina
-
Fujian Medical University Union HospitalRekryteringNeurodegenerativ störningKina
-
Oriental Neurosurgery Evidence-Based-Study TeamOkändNeurodegenerativ demensKina
-
University of California, San FranciscoAnmälan via inbjudanFriska | Neurodegenerativ sjukdomFörenta staterna
-
National Institute of Mental Health (NIMH)RekryteringAutism | Neurologiska störningar | Neurodegenerativ sjukdom | Neurobehavioral manifestationFörenta staterna
-
Centre Hospitalier Universitaire, AmiensRekryteringStroke | Kognitiv neurodegenerativ | Verbala flytande störningarFrankrike
-
National Institute of Neurological Disorders and...AvslutadParkinsons sjukdom | Neurodegenerativ sjukdomFörenta staterna
Kliniska prövningar på florbetapir F 18
-
Brigham and Women's HospitalAvslutadHjärtamyloidosFörenta staterna
-
Avid RadiopharmaceuticalsIndragenAlzheimers sjukdomJapan
-
Avid RadiopharmaceuticalsAvslutadProgressiv kognitiv försämringFörenta staterna
-
Avid RadiopharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS); National...AvslutadParkinsons sjukdomFörenta staterna
-
Avid RadiopharmaceuticalsAvslutadAlzheimers sjukdomFörenta staterna
-
Avid RadiopharmaceuticalsAvslutad
-
Avid RadiopharmaceuticalsAvslutadLätt kognitiv funktionsnedsättning | Alzheimers sjukdomFörenta staterna
-
Chang Gung Memorial HospitalOkänd
-
Avid RadiopharmaceuticalsEli Lilly and CompanyAvslutad
-
Avid RadiopharmaceuticalsAvslutadAlzheimers sjukdomFörenta staterna